Alerts will be sent to your verified email
Verify Email
TRIMURTHI
|
Novelix Pharma
|
Prospect Consumer
|
Swadeshi Inds & Leas
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
-17.5 % | 0.35 % | -4.47 % |
|
5yr Avg Net Profit Margin
|
-14.11 % | 3.81 % | -69.5 % |
|
Price to Book
|
8.2 | 0.0 | 6.58 |
|
P/E
|
103.07 | 27.0 | 44.61 |
|
5yr Avg Cash Conversion Cycle
|
29.1 Days | 119.16 Days | -17.53 Days |
|
5yr Average Interest Coverage Ratio
|
-17.77 | 3.46 | -350.01 |
|
5yr Avg ROCE
|
-15.4 % | 4.07 % | -4.45 % |
|
5yr Avg Operating Profit Margin
|
-16.49 % | 7.96 % | -75.84 % |
|
5 yr average Debt to Equity
|
0.05 | 0.13 | 0.0 |
|
5yr CAGR Net Profit
|
35.78 % | n/a | -19.73 % |
|
5yr Average Return on Assets
|
-13.36 % | -0.14 % | -4.09 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
52.75 % | 50.92 % | 34.97 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
-14.17 % | -11.02 % | 6.49 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Novelix Pharma
|
Prospect Consumer
|
Swadeshi Inds & Leas
|
|---|